Recent Updates — FIXX

Q32 Bio presented additional 36-week results and initial findings from the 16-week off-drug period for Part B of its SIGNAL-AA Phase 2a clinical trial evaluating bempikibart in severe alopecia areata. At Week 36, 44% of patients achieved a SALT-50 response (50% improvement in scalp hair coverage), and the drug demonstrated robust durability with maintained or deepened responses during the off-drug follow-up period. The data supports advancing bempikibart into a registration-directed program in the first half of 2027. Q32 Bio is a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune diseases.

Q32 Bio Inc. announced the appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer on September 14, 2026. Dr. Trevejo joins from Enveda Therapeutics, where he served as CMO and Head of Clinical Pipeline Strategy, having previously held leadership roles at Tarsus Pharmaceuticals and Rocket Pharmaceuticals. Dr. Hershberger comes from EMH Consulting LLC after serving as Chief Development Officer at Adagio Therapeutics (now Invivyd). These hires support the company's transition to late-stage clinical development for its lead candidate, bempikibart, a fully human anti-IL-7Rα antibody being evaluated for alopecia areata and other autoimmune diseases. Q32 Bio is a clinical-stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases.